This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
by Zacks Equity Research
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
by Zacks Equity Research
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
by Kinjel Shah
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
Top Research Reports for Exxon Mobil, Mastercard and Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Mastercard Incorporated (MA) and The Procter & Gamble Company (PG), as well a micro-cap stock Vaso Corporation (VASO).
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
by Zacks Equity Research
Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.
Are Medical Stocks Lagging Eli Lilly (LLY) This Year?
by Zacks Equity Research
Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
by Zacks Equity Research
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Stocks to Buy and Hold for 5 Years
by Tracey Ryniec
What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
by Zacks Equity Research
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?